{"nctId":"NCT00375492","briefTitle":"Effect on Weight Loss of Exenatide Versus Placebo","startDateStruct":{"date":"2006-09"},"conditions":["Type 2 Diabetes Mellitus"],"count":196,"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide"]},{"label":"Group B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"exenatide","otherNames":["Byetta"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes for at least 6 months\n* Have been treated with a stable dose of the following for at least 6 weeks prior to screening: \\*immediate or extended release metformin, or \\*a sulfonylurea, or \\*a fixed-dose sulfonylurea/metformin combination therapy\n* Have an HbA1c of 6.6% to 10.0%, inclusive\n* Have a Body Mass Index (BMI) of 25 kg/m\\^2 to 39.9 kg/m\\^2, inclusive\n\nExclusion Criteria:\n\n* Are treated with any of the following excluded medications: \\*exogenous insulin, thiazolidinedione, or alpha-glucosidase inhibitor for more than 1 week within 6 weeks of screening; \\*Symlin injection at any time; \\* Byetta injection within 3 months of screening or discontinuation of therapy at any time due to adverse reaction; \\*drugs that directly affect gastrointestinal motility; \\*use of a weight loss drug (including those available over the counter) within 3 months of screening; \\*chronic (lasting longer than 2 weeks) systemic corticosteroids (excluding topical, intranasal, and inhaled preparations) by oral, intravenous, or intramuscular route within 2 months of screening\n* Have conditions contraindicating metformin and/or sulfonylurea use\n* Have had a change in lipid-lowering agents within 6 weeks of screening\n* Have received glucagon-like peptide-1 (GLP-1) analogs, or dipeptidyl peptidase-IV inhibitors (DPP-IV inhibitors) or have previously participated in this study\n* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Body Weight","description":"Change in body weight from baseline (Week 0) after 24 weeks of treatment (i.e., weight at week 24 minus weight at week 0). Body weight measured in kilograms (k).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.16","spread":"0.54"},{"groupId":"OG001","value":"-3.97","spread":"0.52"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","description":"Change in HbA1c from baseline (Week 0) after 24 weeks of treatment (i.e., HbA1c at week 24 minus HbA1c at week 0). HbA1c is measured as percent (%) of hemoglobin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"0.09"},{"groupId":"OG001","value":"-0.73","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 6-point Self Monitored Blood Glucose (SMBG) Profile at Week 24","description":"Change in SMBG at each of 6 time points throughout a day (blood glucose measurements before and 2 hours after the start of the morning, mid-day, and evening meals); week 24 compared to week 0 (i.e., SMBG at week 24 minus SMBG at week 0). Fasting Glucose measured in millimoles per liter (mmol/L).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.87","spread":"0.17"},{"groupId":"OG001","value":"-1.20","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.67","spread":"0.22"},{"groupId":"OG001","value":"-1.92","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.40","spread":"0.19"},{"groupId":"OG001","value":"-1.37","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.12","spread":"0.21"},{"groupId":"OG001","value":"-1.51","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.57","spread":"0.19"},{"groupId":"OG001","value":"-1.32","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.09","spread":"0.22"},{"groupId":"OG001","value":"-2.28","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference at Week 24","description":"Change in waist circumference from baseline after 24 weeks of treatment (i.e., waist circumference at week 24 minus waist circumference at week 0). Waist measured in centimeters (cm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.33","spread":"0.71"},{"groupId":"OG001","value":"-4.18","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Ratio of Homeostatic Model Assessment-Beta Cell (HOMA-B) at Week 24 to HOMA-B at Baseline","description":"Ratio of HOMA-B at Week 24 to HOMA-B at baseline (Week 0). HOMA-B is a computer solved model used to predict the homeostatic concentrations which arise from varying degrees beta-cell deficiency. HOMA-B allows a quantitative assessment of the contributions of deficient beta cell function to the fasting hyperglycemia. HOMA-B is measured as a percent of the normal population (normal beta cell function = 100%, which is used as a reference in the calculation). The higher the percent the better for the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":"0.12"},{"groupId":"OG001","value":"1.29","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Homeostatic Model Assessment-Insulin Sensitivity (HOMA-S) at Week 24 to HOMA-S at Baseline","description":"Ratio of HOMA-S at Week 24 to HOMA-S at baseline, week 0. HOMA-S is a computer solved model used to predict the homeostatic concentrations which arise from varying degrees of insulin sensitivity. HOMA-S allows a quantitative assessment of the contributions of insulin sensitivity to the fasting hyperglycemia. HOMA-S is measured as a percent of the normal population (normal insulin sensitivity = 100%, which is used as a reference in the calculation). The higher the percent the better for the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"0.07"},{"groupId":"OG001","value":"0.97","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High Density Lipoprotein (HDL) Cholesterol at Week 24","description":"Change in HDL cholesterol from baseline after 24 weeks of treatment (i.e., HDL cholesterol at week 24 minus HDL cholesterol at week 0). HDL measured as mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.02"},{"groupId":"OG001","value":"0.02","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol at Week 24","description":"Change in LDL cholesterol from baseline (Week 0) after 24 weeks of treatment (ie., LDL cholesterol at week 24 minus LDL cholesterol at week 0). LDL cholesterol measured in mmol/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.08"},{"groupId":"OG001","value":"-0.04","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Cholesterol at Week 24","description":"Change in total cholesterol from baseline after 24 weeks of treatment (i.e., total cholesterol at week 24 minus total cholesterol at week 0). Total cholesterol measured in mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.10"},{"groupId":"OG001","value":"-0.03","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Triglycerides at Week 24 to Triglycerides at Baseline","description":"Ratio of triglyceride levels at Week 24 to triglyceride levels at baseline, Week 0 (ie., triglycerides at Week 24 divided by triglycerides at baseline, Week 0). Triglycerides measured in mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.04"},{"groupId":"OG001","value":"0.92","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Hypoglycemic Events During the Study","description":"Number of participants experiencing one or more events of hypoglycemia at any point in the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Hypoglycemic Events","description":"Overall rate of hypoglycemia, adjusted for 1 year (ie., events of hypoglycemia per participant per year).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.14","spread":"1.45"},{"groupId":"OG001","value":"4.58","spread":"1.43"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Nausea","Diarrhea","Upper respiratory tract infection","Vomiting","Headache"]}}}